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Heart failure is a significant health problembecause of its high morbidity, mortality,and cost of treatment. As the proportionof patients surviving cardiac events such
as myocardial infarction increases, the population
with heart failure is expected to continue to expand
and thus, the associated costs of heart failure will
continue to rise.
Heart failure is a progressive disease, characterized
by symptoms that can severely debilitate the patient.
These symptoms arise as a consequence of inadequate
cardiac output and result from multiple and complex
systemic responses that are dominated by reflex acti-
vation of neurohumoral systems, including the renin-
angiotensin-aldosterone and sympathetic nervous sys-
tems. Hypertension is a major risk factor for heart
failure and plays a key role in the evolution of the
disease. As a result of the increased peripheral resis-
tance and enhanced wall tension associated with hy-
pertension, hypertrophy of the left ventricle of the
heart may develop, accompanied by fibrosis, which
then results in reduced contractility. Ultimately the
hypertrophied and fibrosed myocardium is no longer
able to maintain normal cardiac output and failure
occurs.
Early and aggressive treatment of hypertension re-
duces the progression of the disease to heart failure
and therefore, antihypertensive agents have an impor-
tant role in slowing the pathogenic adaptations asso-
ciated with the disease. The central role of angiotensin
II in the regulation of blood pressure is the reason why
inhibitors of the renin-angiotensin system (RAS) have
attracted so much interest both in clinical practice and
research; however, the benefits associated with the use
of angiotensin converting enzyme (ACE) inhibitors
are probably the result of a number of factors, of
which blood pressure reduction is only one.
The observation that physicians still limit their use
of ACE inhibitors suggests that the benefits of antihy-
pertensive treatment with this drug class are underes-
timated. There have been several suggestions trying to
explain the underusage of ACE inhibitors, the most
important of which may be two general misconcep-
tions regarding these agents. One is that they are
expensive and the cost associated with ACE inhibitors
is not justified based on the outcomes they produce,
and the other is that the risk of adverse events asso-
ciated with their use outweighs their benefits. This is
despite significant clinical evidence that demonstrates
the beneficial effects of ACE inhibitors on symptom-
atology, need for hospitalizations and disease progres-
sion in heart failure.
Fosinopril is the first of a new class of ACE inhibi-
tors. Fosinopril does not accumulate in patients with
renal insufficiency attributable to its dual and com-
pensatory renal and hepatic routes of excretion and
this property is of particular interest in patients with
severe hypertension and heart failure. In such pa-
tients, in whom a concomitant decrease in renal func-
tion is often present, compensatory hepatic excretion
of fosinopril is useful as dose adjustments are gener-
ally not necessary in these patients with impaired
ability to excrete drugs through the renal route. In
addition, recent data have suggested that the inci-
dence of cough may be lower with fosinopril com-
pared with other members of this pharmacologic class.
This might suggest that the ACE inhibitor class is not
totally homogenous and that the degree of benefit
produced by various members of this class can be
differentiated.
The treatment of patients with hypertension has
long since moved away from purely controlling blood
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pressure, to considering all risk factors present in a
particular patient. Because hypertensive patients often
have multiple risk factors for cardiovascular disease it
is important to take these into account when initiating
therapy and also to consider possible effects of the
therapeutic agents chosen on such risk factors. For
example, in this context it is interesting that in patients
with non–insulin-dependent diabetes, a combination
of ACE inhibitor plus thiazide can achieve antihyper-
tensive effects without adversely affecting carbohy-
drate and lipid metabolism. The additive action of
ACE inhibitors and diuretics in the treatment of hy-
pertension has, of course, been demonstrated in nu-
merous studies. Such investigations have demon-
strated that the combination is also effective in the
elderly and in renally impaired patients.
The effects of pharmacologic reduction of blood
pressure on cardiovascular events has also been stud-
ied in elderly patients with isolated hypertension.
These elderly patients showed a statistically signifi-
cant reduction in cardiovascular complications. Initial
studies with fosinopril have now also shown that
there is no increase in withdrawal rate as a result of
side effects in these patients. This is particularly im-
portant from a clinical viewpoint, as the elderly fre-
quently have a wide range of morbid conditions and
accordingly take more medicines. This polytherapy
can increase the incidence of drug-related side effects,
partly because of potential drug interactions, but also
because drug accumulation can occur in association
with physiologic deterioration in renal function with
age.
Large clinical trials of antihypertensive treatment
have not clearly demonstrated gender differences in
blood pressure response and outcome; however, the
majority of patients in these trials were men. As with
men, hypertensive women also exhibit an increased
risk for both coronary disease and stroke compared to
normotensive controls; however, the incidence is
lower in women under 65 years of age. For this reason,
there have been discussions relating to whether or not
treatment thresholds should differ between men and
women. Notwithstanding, it is important that hyper-
tension in women be treated as vigorously as in men
to avoid major complications, which have been found
to be associated with a prognosis possibly even worse
than in men.
As a result of the increasing cost of health care and
the limited resources available, it has become more
difficult to allocate resources efficiently and effectively
in the health care system. This environment has led to
the development of pharmacoeconomic studies,
which have been designed in response to the need for
assessment of the economic benefits of a product be-
fore its acceptance in the market. Conventionally, ACE
inhibitors have been considered expensive agents
compared to more longer established agents. Cost ef-
fectiveness analyses of ACE inhibitors for the treat-
ment of heart failure are, however, beginning to show
these agents to be cost-effective by markedly reducing
the cost of hospitalization, diagnostic procedures, and
of the general management of these patients. All in all,
it cannot be emphasized enough that there are prob-
ably few alternative ways of spending health care
money that, in the long term, provide a better return
on investment in terms of quality of life, to providing
elderly patients with hypertension and congestive
heart failure optimal therapy with ACE inhibitors.
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